Maze Therapeutics (MAZE) Cost of Revenue (2024 - 2026)

Maze Therapeutics recorded quarterly Cost of Revenue of $1.8 million in Q1 2026, up 50.97% quarter-over-quarter from $1.2 million in Q1 2025, and up 50.97% year-over-year from $1.2 million in Q1 2025.

Maze Therapeutics' Cost of Revenue history runs 3 years deep, the most recent figure standing at $1.8 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 64.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 392.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 296.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 207.52 Mn
10 Maze Therapeutics 1.37 Bn 1.37 Bn 18.21 Mn 1.79 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.79 Mn
Mar 31, 2026 1.79 Mn
Mar 31, 2025 1.19 Mn
Mar 31, 2025 1.19 Mn
Mar 31, 2024 1.28 Mn
Mar 31, 2024 1.28 Mn